Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment
Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment and Possible Mechanisms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yin-Ching Chan, PhD
- Phone Number: 886921376777
- Email: ycchan@pu.edu.tw
Study Contact Backup
- Name: Juen-Haur Hwang, MD, PhD
- Phone Number: 886928834922
- Email: G120796@tzuchi.com.tw
Study Locations
-
-
Chiayi
-
Dalin, Chiayi, Taiwan, 622
- Recruiting
- Departments of Otolaryngology and Neurosurgery of Dalin Tzu Chi Hospital
-
Contact:
- Juen-Haur Hwang, MD, PhD
- Phone Number: 886928834922
- Email: G120796@tzuchi.com.tw
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB.
Exclusion Criteria:
- Patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment , patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hericium honey bolus
Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
|
The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
|
|
Placebo Comparator: Control group
Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
|
The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1.Change of Tinnitus status evaluates by Tinnitus handicap inventory (THI)
Time Frame: Baseline, 4th month and 8th month
|
The status of tinnitus will be evaluated by Tinnitus handicap inventory (THI).
THI is divided into three categories, including the functional (12 questions), emotional (8 questions), and catastrophic (5 questions) subscore.
A total of 25 questions are used.
The answer will be divided into three levels (will, sometimes, will not), and be scored into 4, 2 and 0 point, respectively.
The subscore of functional (12 questions), emotional (8 questions), and catastrophic (5 questions) are 48, 32, and 20, respectively.
The highest total score is 100 points.
The higher the score, the more the tinnitus is.
The difference of score will be compared from the baseline with 4th and 8th month.
|
Baseline, 4th month and 8th month
|
|
Change of Tinnitus severity evaluates by visual analog scale (VAS)
Time Frame: Baseline, 4th month and 8th month
|
The severity of tinnitus will be scored with a visual analog scale (VAS) from point 0 to point 10 by subject.
The difference of score will be compared from the baseline with 4th and 8th month.
|
Baseline, 4th month and 8th month
|
|
Changes of hearing obstacle average measure by Pure Tone Audiometry(PTA)
Time Frame: Baseline, 4th month and 8th month
|
Pure tone threshold of subjects will be measured by Pure Tone Audiometry (PTA) to evaluate the changes from baseline ageing hearing obstacle average (dB HL) with 4th and 8th month.
|
Baseline, 4th month and 8th month
|
|
Changes of speech recognizing measure by Speech Audiometry.
Time Frame: Baseline, 4th month and 8th month
|
The Speech Audiometry is used to evaluate the changes of baseline speech recognizing (dB HL) and speech speech recognition rate(%) with 4th and 8th month.
|
Baseline, 4th month and 8th month
|
|
Changes of NGF and BDNF levels of blood investigate by enzyme-linked immunosorbent assay (ELISA)
Time Frame: Baseline, 4th month and 8th month
|
The NGF and BDNF levels of blood will be analyzed by enzyme-linked immunosorbent assay (ELISA) to detect the presence of NGF and BDNF.
The NGF and BDN levels will be quantitative by the optical density (OD) of the sample comparing to a standard curve, which is a serial dilution of a known-concentration solution of the target molecule.
The difference of NGF and BDNF levels will be compared from the baseline with 4th and 8th month.
|
Baseline, 4th month and 8th month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yin-Ching Chan, Providence University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B10604025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.